公开(公告)号：KR101391777B1

公开(公告)日：2014-05-07

申请号：KR1020110036727

申请日：2011-04-20

Applicant: 삼육대학교산학협력단

Inventor： 정재훈 ,  우태선 ,  류종훈 ,  최재수

IPC: A61K36/282 ,  A61P21/02 ,  A61P25/24 ,  A61P25/00

Abstract: 본발명은경련성질환치료및 예방용약학조성물에관한것으로서, 더욱구체적으로는인진호추출물또는인진호추출물의유효성분인카필라리신(capillarisin) 및/또는에스쿨레틴(esculetin)의항경련효과에대한것이며, 특히생약에서유래된성분으로, 인체에안전하며용량이증가할수록경련억제효과가증가하므로인체에과량사용해도부작용이적은약학조성물에관한것이다.

公开(公告)号：KR1020120119014A

公开(公告)日：2012-10-30

申请号：KR1020110036727

申请日：2011-04-20

Applicant: 삼육대학교산학협력단

Inventor： 정재훈 ,  우태선 ,  류종훈 ,  최재수

IPC: A61K36/282 ,  A61P21/02 ,  A61P25/24 ,  A61P25/00

CPC classification number: A61K36/282 ,  A61K2236/333

Abstract: PURPOSE: A pharmaceutical composition for treating and preventing convulsive disorder containing artemisiae capillaris herba extracts is provided to be safe for human body and to reduce side effects even when the composition is excessively used. CONSTITUTION: A pharmaceutical composition for treating and preventing convulsive disorder contains artemisiae capillaris herba extracts. A pharmaceutical composition for alleviating and preventing spasmolysis includes the artemisiae capillaris herba extracts. The artemisiae capillaris herba extract is extracted by using 60-80% of ethanol as an active ingredient. The artemisiae capillaris herba extracts include capillarisin or esculetin as the active ingredient. The convulsive disorder is non-traumatic stroma depression, anxiety disorders or psychosis failure. The convulsive disorder is a disease which can be treated or prevented according to the increase of Cl- inflow in cells. The convulsive disorder is prevented or treated by control of gamma-amino butyric acid receptor. [Reference numerals] (AA) The first group (con.); (BB) The second group (practical example 1, 50mg/kg); (CC) The third group (practical example 1, 100mg/kg); (DD) The fourth group (practical example 1, 200mg/kg); (EE) The fifth group (DZP, 5mg/kg); (FF) Tonic extension reaction(%); (GG) Current (mA)

Abstract translation: 目的：提供一种用于治疗和预防含有青蒿提取物的惊厥症的药物组合物，以便即使在过量使用组合物时也能减轻副作用。 构成：用于治疗和预防惊厥性疾病的药物组合物含有蒿蒿提取物。 用于缓解和预防解痉的药物组合物包括蒿蒿提取物。 通过使用60-80％的乙醇作为活性成分提取青蒿提取物。 青蒿提取物包括毛利利素或七叶亭素作为活性成分。 惊厥性疾病是非创伤性基质抑郁症，焦虑障碍或精神病失效。 惊厥症是根据细胞中Cl-流入量的增加可以治疗或预防的疾病。 通过控制γ-氨基丁酸受体来预防或治疗惊厥性疾病。 （附图标记）（AA）第一组（con。）; （BB）第二组（实施例1,50mg / kg）; （CC）第三组（实施例1，100mg / kg）; （DD）第四组（实施例1,200mg / kg）; （EE）第五组（DZP，5mg / kg）; （FF）延伸反应（％）; （GG）电流（mA）